佐力药业(300181) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥439,416,764.79, representing a 29.18% increase compared to ¥340,156,986.02 in the same period last year[3] - Net profit attributable to shareholders was ¥68,746,697.37, a 56.97% increase from ¥43,795,349.24 year-on-year[3] - Basic earnings per share increased to ¥0.1130, a rise of 56.94% compared to ¥0.0720 in the same period last year[3] - Operating profit for the quarter was ¥82,902,600.00, a 52.59% increase from the previous year, driven by significant sales revenue growth[9] - Net profit for the current period was ¥72,755,387.42, compared to ¥47,076,899.11 in the previous period, reflecting a growth of approximately 54.5%[30] Cash Flow - The net cash flow from operating activities reached ¥85,732,512.56, up 80.08% from ¥47,608,885.33 in the previous year[3] - Cash flow from operating activities generated a net amount of 85,732,512.56 CNY, up from 47,608,885.33 CNY in the previous period, reflecting improved operational efficiency[35] - Cash inflow from operating activities totaled 439,531,004.52 CNY, compared to 361,862,270.26 CNY in the prior year, showing a growth of approximately 21.5%[38] - Cash outflow for operating activities was 353,798,491.96 CNY, an increase from 314,253,384.93 CNY, resulting in a net cash flow increase[38] - The net cash flow from financing activities was 3,803,919.20 CNY, a recovery from a negative cash flow of -60,262,357.03 CNY in the prior year[41] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,546,426,648.49, down 7.35% from ¥2,748,532,182.07 at the end of the previous year[3] - Total liabilities decreased from ¥765,314,231.14 to ¥703,858,997.17, a reduction of about 8.0%[26] - The equity attributable to shareholders of the parent company decreased from ¥1,844,064,465.20 to ¥1,716,307,390.04, a decline of approximately 6.9%[26] Research and Development - The company's R&D expenses for the quarter were ¥1,166.45 million, reflecting a 65.93% increase year-on-year[6] - Research and development expenses amounted to ¥11,664,510.89, which is an increase from ¥7,029,897.49, showing a rise of about 66.5%[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 59,345, with the largest shareholder, Yu Youqiang, holding 21.34% of shares, amounting to 129,890,463 shares[10] - The company has a total of 10 major shareholders, with a combined holding of 99.9957% of shares[13] - The company has no shareholders participating in margin trading or securities lending activities[13] Comprehensive Income - The company’s other comprehensive income showed a significant loss of ¥212,427,327.03 compared to a gain of ¥117,082,950.24 in the previous period[30] - The total comprehensive income attributable to the parent company was -127,757,077.23 CNY, compared to 152,101,761.53 CNY in the previous period, indicating a significant decline[34] Inventory and Receivables - The company experienced a 20.76% increase in accounts receivable, totaling ¥362,183,100.00, primarily due to increased sales revenue[6] - Accounts receivable increased to ¥362,183,077.03 from ¥299,924,697.18, reflecting a growth of about 20.7%[19] - Inventory decreased to ¥249,977,579.57 from ¥273,588,868.56, indicating a reduction of approximately 8.6%[19] Financial Audit - The company did not conduct an audit for the first quarter report, which may affect the reliability of the financial data presented[42]